Firstchoice Healthcare PC
Firstchoice Healthcare PC was paid $3.02M by Medicaid between Jan 2018 and Aug 2019, across 45 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider infoFIRSTCHOICE HEALTHCARE PC
EASLEY, SC 29642
EASLEY, SC 29642
33aNPI1912001264assigned 09/08/2006
33bProvider typeChiropractor
28Total paid$3.02M
24GClaims84,874
24DCodes billed45
24AFirst – last monthJan 2018 – Aug 2019
Compared with peers
Next to other Chiropractor providers in South Carolina
Rank by total paid#1 of 29
Median peer was paid$2K
This provider vs. median1,919×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,014 | $2.20M | |
| 2019 | 22,860 | $819K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 30,471 | 27,925 | $855K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 28% | 22,597 | 20,974 | $842K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 13% | 6,362 | 6,185 | $385K |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg | 8.2% | 4,555 | 3,713 | $248K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 7.7% | 4,141 | 3,944 | $233K |
| 95886 | 2.3% | 1,654 | 1,513 | $70K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 869 | 825 | $55K |
| 95913 | 1.6% | 668 | 596 | $48K | |
| 95912 | 1.3% | 688 | 663 | $39K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.2% | 696 | 665 | $36K |
| 99205 | Prolong outpt/office vis | 1.0% | 369 | 360 | $31K |
| 62323 | 1.0% | 548 | 443 | $30K |
33 more codes
| 72110 | <1% | 1,518 | $25K | |
| 64493 | <1% | 642 | $20K | |
| 20610 | <1% | 1,120 | $18K | |
| 64483 | <1% | 239 | $13K | |
| 77002 | <1% | 775 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,270 | $10K |
| 72050 | <1% | 499 | $8K | |
| 64494 | <1% | 504 | $8K | |
| 27096 | <1% | 131 | $6K | |
| 64635 | <1% | 88 | $6K | |
| 95911 | <1% | 93 | $5K | |
| 99152 | <1% | 391 | $4K | |
| 64636 | <1% | 89 | $3K | |
| 20553 | <1% | 107 | $2K | |
| 64495 | <1% | 131 | $2K | |
| 73564 | <1% | 107 | $1K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 169 | $754.15 |
| 73562 | <1% | 40 | $661.26 | |
| 62321 | <1% | 13 | $636.90 | |
| 72100 | <1% | 59 | $634.33 | |
| 64490 | <1% | 12 | $591.91 | |
| 73030 | <1% | 58 | $580.13 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,977 | $557.82 |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 14 | $549.60 |
| 98926 | <1% | 25 | $381.25 | |
| J7321 | Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | <1% | 24 | $369.05 |
| 64491 | <1% | 12 | $292.56 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 482 | $205.39 |
| 82962 | <1% | 224 | $187.17 | |
| 72070 | <1% | 13 | $73.72 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 395 | $54.99 |
| 73502 | <1% | 16 | $46.10 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, LLOYD (5 OWNER)